TY - JOUR T1 - Recurrent respiratory papillomatosis - rapid response to systemic bevacizumab JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - 1798 AU - Christoph Schliemann AU - Christoph Biermann AU - Andreas Hilbis AU - Thorsten Kessler AU - Joachim Schmidt AU - Karsten Wiebe AU - Klaus-Michael Müller AU - Thomas K. Hoffmann AU - Claudius Werner AU - Andreas H. Groll AU - Christina Kessler AU - Rainer Wiewrodt AU - Claudia Rudack AU - Berdel Wolfgang AU - Michael Mohr Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/1798.abstract N2 - Recurrent respiratory papillomatosis (RRP) is a potentially devastating, non-curable disease caused by infection with human papilloma virus (HPV), mainly HPV-6 and -11. Manifestations of RRP can occur everywhere in the respiratory tract and may lead to laryngeal, tracheal or bronchial obstructions, pulmonary nodes and cystic lesions due to valve effects. Malignant transformation occurs in 3 to 5% of the cases. Long-term management of patients with recurrent respiratory papillomatosis (RRP) remains challenging. Local debulking is the current treatment of choice and antiviral therapy is a possible adjuvant approach. Here, we report an immediate and sustained therapeutic effect of systemically applied bevacizumab without further local treatment in a series of five consecutive patients (7-56y) with RRP. In all cases, a rapid response to the first infusion of bevacizumab could be documented bronchoscopically within a few days.Continued anti-VEGF treatment resulted in sustained (very good) partial responses of tracheal or laryngeal papilloma manifestations. Due to limited alternatives VEGF-targeted therapies represent a promising novel strategy in the treatment of RRP and should be further investigated in clinical trials. ER -